[Changes in markers of autoimmunity in patients with Hashimoto thyroiditis treated with intravenous immunoglobulins. Preliminary results].
We have evaluated the variations of thyroid function, of thyroid autoantibodies titer, of non-organ specific autoantibodies and of other autoimmunity indices in 3 patients affected with Hashimoto's thyroiditis treated with "high dose intravenous gammaglobulin" (IVIG) (400 mg/Kg/day for 3 cycles of 5 days and subsequently 9-12 cycles of 1 day every 21 days). Before the starting of IVIG treatment patient 1 presented clinically evident hypothyroidism while patients 2 and 3 presented a preclinical form of hypothyroidism. At the end of IVIG treatment patients presented no variation of thyroid function, while patients 2 and 3 presented a normalization of T3, T4 and TSH circulating levels. Before the starting of IVIG treatment thyroglobulin antibodies (TgAb) were positive in 3/3 patients, microsomal antibodies (MAb) were positive in 3/3 patients adt TRAb were positive in 2/3 patients and MAb titre was decreased or negative in 0/3 patients. At the end of IVIG treatment Tg Ab titre was decreased or negative in 2/3 patients and MAb titre was decreased or negative in 2/3 patients. Anti-nuclear antibodies (ANA) 1/3 patients before the titre and in all these we observed a reduction or negativization of circulating titre during IVIG treatment. Anti-extractable nuclear antigen (ENA), anti-mitochondrial antibodies (AMA), C3, C4, CH50 and rheumatoid factors were negative or in the normal range in all the patients. In conclusion these data suggest that IVIG is effective in the treatment of preclinical hypothyroidism in patients with Hashimoto's thyroiditis and determine a stable immunosuppressive action on circulating thyroid and non organ specific autoantibodies.
Antonelli
A
A
Istituto di Clinica Medica, Università degli Studi di Pisa.
Alberti
B
B
Melosi
A
A
Saracino
A
A
Agostini
S
S
Gambuzza
C
C
Neri
S
S
Baschieri
L
L
D001323:Autoantibodies / Q000097:blood*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008861:Microsomes / Q000276:immunology; D013954:Thyroglobulin / Q000276:immunology; D013963:Thyroid Hormones / Q000097:blood*; D013967:Thyroiditis, Autoimmune / Q000097:blood* / Q000276:immunology / Q000628:therapy*
D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D013963:Thyroid Hormones; D013954:Thyroglobulin
Modificazioni dei markers di autoimmunità in pazienti affetti da tiroide di Hashimoto trattati con immunoglobuline per via endovenosa. Risultati preliminari.